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Abstract: Swiprosin-1 (EFhD2) is a molecule that triggers structural adaptation of isolated adult rat
cardiomyocytes to cell culture conditions by initiating a process known as cell spreading. This process
mimics central aspects of cardiac remodeling, as it occurs subsequent to myocardial infarction.
However, expression of swiprosin-1 in cardiac tissue and its regulation in vivo has not yet been
addressed. The expression of swiprosin-1 was analyzed in mice, rat, and pig hearts undergoing
myocardial infarction or ischemia/reperfusion with or without cardiac protection by ischemic pre-
and postconditioning. In mouse hearts, swiprosin-1 protein expression was increased after 4 and 7 days
in myocardial infarct areas specifically in cardiomyocytes as verified by immunoblotting and histology.
In rat hearts, swiprosin-1 mRNA expression was induced within 7 days after ischemia/reperfusion
but this induction was abrogated by conditioning. As in cultured cardiomyocytes, the expression of
swiprosin-1 was associated with a coinduction of arrestin-2, suggesting a common mechanism of
regulation. Rno-miR-32-3p and rno-miR-34c-3p were associated with the regulation pattern of both
molecules. Moreover, induction of swiprosin-1 and ssc-miR-34c was also confirmed in the infarct zone
of pigs. In summary, our data show that up-regulation of swiprosin-1 appears in the postischemic
heart during cardiac remodeling and repair in different species.
Keywords: cardiac regeneration; cardiac protection; miR-34
1. Introduction
Swiprosin-1, also known as EF-Hand domain family member D2 (EFhd2), acts as a calcium
sensor that stabilizes F-actin filaments by blocking binding sites of cofilin [1]. Cofilin is needed
for the depolymerization of F-actin [2]. Expression of swiprosin-1 has already been identified in
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lymphocytes, B-cells, mast cells, T-cells, neurons, podocytes, and cardiomyocytes [3–9]. Furthermore,
a drosophila-specific homologue of human swiprosin-1 participates in skeletal muscle formation [10].
In immune cells, it triggers the formation of lamellopodia, which is required for migration of
macrophages [11]. In neurons, swiprosin-1 regulates the cargo capacity of kinesin and participates in
neuronal outgrow [1]. In cardiomyocytes, swiprosin-1 is required for the formation of pseudopodia-like
structures [9,12]. Pseudopodia-like structures enable adult rat ventricular cardiomyocytes to adapt
to culture dishes, to stay alive for days, and to rearrange their sarcomeres by adaptation from
the three-dimensional heart to the two-dimensional surrounding of culture dishes. At the level of
swiprosin-1 regulation, changes in the mRNA levels went parallel with those of protein expression,
suggesting transcriptional regulation. However, the more important consequence of this observation
is that this process mimics aspects of cardiac remodeling. Extensive cardiac remodeling with global
cardiac changing in gene expression occurs subsequently to myocardial infarction (MI) when repair
processes occur [13–15]. Therefore, in the present study we investigated the expression of swiprosin-1
in cardiac tissue during subsequent cardiac remodeling.
Among the common features between cardiac tissue repair and cellular adaptation of terminal
differentiated cardiomyocytes to culture conditions are a desensitization of β-adrenoceptors that can
be modified by ischemic postconditioning (IPoC) [16]. Similarly, β-adrenoceptor responsiveness is
reduced during cellular adaptation of cardiomyocytes to cultivation. In line with this observation,
swiprosin-1 was found to be strongly coregulated under culture conditions with molecules that
regulate β-adrenoceptor responsiveness, such as β-arrestin-2 [9]. This coregulation suggests a common
mechanism of regulation for both genes. Nowadays, micro-RNAs (miRs) have been identified as
potential molecules that coordinate the several proteins acting together to modify the phenotype of
individual cells. They bind to mRNA and abrogate subsequent translation into protein. Therefore,
we also screened for potential miRs that may commonly be involved in the coregulation of swiprosin-1
and β-arrestin-2.
2. Results
2.1. Swiprosin-1 Expression In Post-Infarcted Mice
Although swiprosin-1 expression and its role in cellular adaptation has been documented before [9],
the relevance of these in vitro findings for cardiac repair processes remained unclear. Therefore, we first
investigated the expression of swiprosin-1 in post-MI hearts. Experiments were performed on mouse
hearts previously used for investigating the role of oncostatin M in cardiac repair, because in cultured
cardiomyocytes swiprosin-1 and oncostatin M are coregulated. Immunoblotting of myocardial tissue
samples of infarcted mice specified an increased expression of swiprosin-1 within the infarcted
region when compared with the noninfarcted remote myocardium (Figure 1A). Of note, elevated
levels of swiprosin-1 were maintained throughout the first week of cardiac remodeling (Figure 1A).
Immunofluorescence analysis of infarcted hearts further allocated increased expression of swiprosin-1
in preserved cardiomyocytes surrounding the infarct scar, whereas swiprosin-1 was barely detectable
in cardiomyocytes of distal noninfarcted regions (Figure 1B).
2.2. Induction of Swiprosin-1 in Rat Hearts after Ischemia/Reperfusion
In order to address the question of whether induction of cardiac expression of swiprosin-1 in post
ischemic hearts is related to the extent of cardiac repair, swiprosin-1 mRNA expression was analyzed
next in rat hearts 7 days after ischemia/reperfusion (I/R). These hearts have previously been used to
establish the effect of ischemic pre- and postconditioning on cardiac remodeling [17]. Here, we show
that swiprosin-1 mRNA expression is induced by I/R. However, either ischemic preconditioning (IPC)
or IPoC abrogate this induction (Figure 2A). IPC and IPoC have proven effects on infarct sizes as
quantified by troponin I plasma levels 1 h after reperfusion [17]. The mRNA expression of swiprosin-1
showed a linear relationship to the infarct size, suggesting that the amount of expression is related
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to cardiac repair processes (Figure 2B). In vitro, swiprosin-1 mRNA expression in cardiomyocytes is
associated with a similar expression level of arrestin-2. In the cardiac tissue used to quantify the mRNA
expression of swiprosin-1, a similar linear correlation between swiprosin-1 and arrestin-2 was found
(Figure 2C).Int. J. Mol. Sci. 2020, 21, x  3 of 14 
 
 
Figure 1. Expression of swiprosin-1 after the onset of myocardial infarction in adult mice. (A) 
Representative Western Blot analysis of swiprosin-1 in myocardial tissue from adult mice 
fractionated in noninfarct remote zone (RZ) and infarction zone (IZ) at days 4 and 7 after myocardial 
infarction (post-MI). (B) Quantification of the two Western Blots showed by A with *, p < 0.05 vs. RZ; 
(C) Immunofluorescence analysis of swiprosin-1 (green) in infarcted hearts from mice 4 days 
post-MI. Viable cardiomyocytes were stained with ACTN2 (grey) and lectin (red). 
4′,6-diamidino-2-phenylindole (DAPI) was used for nuclear staining (blue). White arrows classify 
swiprosin-1 immunopositive cardiomyocytes. Scale bars: 100 µm and 20 µm in magnified sections. 
2.2. Induction of Swiprosin-1 in Rat Hearts after Ischemia/Reperfusion 
In order to address the question of whether induction of cardiac expression of swiprosin-1 in 
post ischemic hearts is related to the extent of cardiac repair, swiprosin-1 mRNA expression was 
analyzed next in rat hearts 7 days after ischemia/reperfusion (I/R). These hearts have previously 
been used to establish the effect of ischemic pre- and postconditioning on cardiac remodeling [17]. 
Here, we show that swiprosin-1 mRNA expression is induced by I/R. However, either ischemic 
preconditioning (IPC) or IPoC abrogate this induction (Figure 2A). IPC and IPoC have proven effects 
on infarct sizes as quantified by troponin I plasma levels 1 h after reperfusion [17]. The mRNA 
expression of swiprosin-1 showed a linear relationship to the infarct size, suggesting that the amount 
of expression is related to cardiac repair processes (Figure 2B). In vitro, swiprosin-1 mRNA 
Figure 1. Expression of swiprosin-1 after the onset of myocardial infarction in adult mice.
(A) Representative Western Blot analysis of swiprosin-1 in myocardial tissue from adult mice
fractionated in noninfarct remote zone (RZ) and infarction zone (IZ) at days 4 and 7 after myocardial
infarction (post-MI). (B) Quantification of the two Western Blots showed by A with *, p < 0.05 vs. RZ;
(C) Immunofluorescence analysis of swiprosin-1 (green) in infarcted hearts from mice 4 days post-MI.
Viable cardiomyocytes were stained with ACTN2 (grey) and lectin (red). 4′,6-diamidino-2-phenylindole
(DAPI) was used for nuclear staining (blue). White arrows classify swiprosin-1 immunopositive
cardiomyocytes. Scale bars: 100 µm and 20 µm in magnified sections.
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Figure 2. Expression of swiprosin-1 mRNA in the left ventricle from rats seven days after I/R. (A), 
Box plots showing the level of expression and distribution of samples from sham surgery (Sham), 
ischemia/reperfusion (I/R), ischemic preconditioning (IPC), and ischemic postconditioning (IPoC). 
Data are analyzed by One-Way-ANOVA with Student–Newman–Keuls post-hoc analysis (a; p < 0.05 
vs. all other groups). (B); Correlation between infarct sizes as quantified by troponin I release into the 
plasma 60 min after reperfusion and swiprosin-1 mRNA expression. (C) Correlation between 
arrestin-2 mRNA expression and swiprosin-1 mRNA expression. 
Coregulation of swiprosin-1 and arrestin-2 suggests a common mechanism of regulation, such 
as by miR. In the rat heart tissue used for this study, 364 miRs were constitutively detected in all 
samples. Among them, 27 miRs were either positively (n = 15) or negatively (n = 12) associated with 
the mRNA expression of swiprosin-1 (Table 1). However, only 12 of 27 miRs showed an 
Figure 2. Expression of swiprosin-1 mRNA in the left ventricle from rats seven days after I/R.
(A), Box plots showing the level of expression and distribution of samples from sham surgery (Sham),
ischemia/reperfusion (I/R), ischemic preconditioning (IPC), and ischemic postconditioning (IPoC).
Data are analyzed by One-Way-ANOVA with Student–Newman–Keuls post-hoc analysis (a; p < 0.05
vs. all other groups). (B); Correlation between infarct sizes as quantified by troponin I release into
the plasma 60 min after reperfusion and swiprosin-1 mRNA expression. (C) Correlation between
arrestin-2 mRNA expression and swiprosin-1 mRNA expression.
Coregulation of swiprosin-1 and arrestin-2 suggests a common mechanism of regulation, such as
by miR. In the rat heart tissue used for this study, 364 miRs were constitutively detected in all
samples. Among them, 27 miRs were either positively (n = 15) or negatively (n = 12) associated
with the mRNA expression of swiprosin-1 (Table 1). However, only 12 of 27 miRs showed
an ischemia/reperfusion-dependent regulation such as swiprosin-1, and only in two cases could
the induction of miR be abrogated by IPC or IPoC as found for swiprosin-1. These two most likely
candidates were rno-miR-32-3p and rno-miR-34c-3p (Figure 3A,B).
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Table 1. Correlation between swiprosin-1 mRNA and micro-RNAs (miRs).
rno-miR R-Coefficient p-Value I/R IPC/IPoC
Positive Correlation
32-3p r = 0.596 p = 0.003 yes yes
34c-3p r = 0.495 p = 0.016 yes yes
18a-3p r = 0.465 p = 0.025 yes no
23b-5p r = 0.475 p = 0.022 yes no
27b-5p r = 0.436 p = 0.038 yes no
100-3p r = 0.431 p = 0.040 no -
146a-5p r = 0.454 p = 0.029 no -
296-5p r = 0.474 p = 0.022 no -
324-5p r = 0.520 p = 0.011 no -
342-3p r = 0.516 p = 0.012 no -
455-3p r = 0.453 p = 0.030 no -
497-5p r = 0.458 p = 0.028 no -
505-5p r = 0.436 p = 0.038 no -
532-3p r = 0.514 p = 0.012 no -
674-5p r = 0.616 p = 0.002 no -
Negative Correlation
7b
24-2-5p r = -0.475 p = 0.022 no -
29b-3p r = -0.425 p = 0.043 yes no
33-5p r = -0.563 p = 0.005 yes no
99a-5p r = -0.431 p = 0.040 yes no
145-3p r = -0.520 p = 0.011 yes no
150-5p r = -0.414 p = 0.050 yes no
186-5p r = -0.425 p = 0.043 no -
194-5p r = -0.495 p = 0.016 yes no
339-3p r = -0.447 p = 0.033 yes no
345-3p r = -0.426 p = 0.042 no -
3068-5p r = -0.422 p = 0.045 yes no
As expected from the observed coregulation, the mRNA expression of swiprosin-1 showed a linear
correlation with the amount of rno-miR-32-3p and rno-miR-34c-3p in these samples (Figure 4A).
Moreover, both miRs showed a linear correlation with the infarct size (quantified as troponin I plasma
concentration 1 h after I/R) and with arrestin-2 mRNA expression as well (Figure 4B,C).
In the cardiac tissue used for this analysis, mRNA expression of 72 different genes related to
cardiac biology was analyzed (see ref. 17). A detailed analysis of further coregulated mRNAs with
both miRs was performed by investigating a potential linear correlation between mRNAs and miRs.
Interestingly, rno-miR-32-3p showed a positive correlation with genes associated with hypertrophy
and fibrosis and a negative correlation with sodium–calcium exchanger (NCX) (Table 2). The data
suggest that the increased expression of rno-miR-32-3p contributes to the maladaptive phenotype of
cardiac adaptation in these hearts. In contrast, rno-miR-34c-3p displayed a nearly exclusive coregulation
with swiprosin-1 and arrestin-2 (Table 2).
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Figure 3. Expression of rno-miR-32-3p (A) and rno-miR-34c-3p (B) in the left ventricle from rats
seven days after I/R. A). Box plots showing the level of expression and distribution of samples
from sham surgery (Sham), ischemia/reperfusion (I/R), ischemic preconditioning (IPC), and ischemic
postconditioning (IPoC). Data are analyzed by One-Way-ANOVA with Student–Newman–Keuls
posthoc analysis (a; p < 0.05 vs. all other groups).
Figure 4. Cont.
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Figure 4. Correlation between swiprosin-1 mRNA (A), infarct size (as quantified by troponin I plasma
concentration) (B), and arrestin-2 (C), with the abundancy of rno-miR-32-3p and rno-miR-34c-3p.
Table 2. Correlation between miRs and mRNAs.
rno-miR-32-3p
Swiprosin-1 r = 0.596 p = 0.003
Arrestin-2 r = 0.585 p = 0.003
Biglycan
Collagen-1 r = 0.581 p = 0.004
Collagen-3 r = 0.515 p = 0.020
Fibronectin r = 0.452 p = 0.030
Arginase-2 r = 0.434 p = 0.038
iNOS
RAMP-3
MHC-α
NCX
Troponin T r= -0.470 p = 0.023
HADHA
UCP-2
Slc5a3
rno-miR-34c-3p
Swiprosin-1 r = 0.495 p = 0.016
Arrestin-2 r = 0.440 p = 0.036
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Table 2. Cont.
rno-miR-34c-3p
ANP
MHC-α
Elfn2
Kcnh5
Slc5a3
Socs7
Abbreviations: NOS, nitric oxide synthase; RAMP, receptor associated modifying protein; ANP, atrial natriuretic
peptide; MHC; myosin heavy chain; Elfn, extracellular leucine rich repeat and fibronectin type III domain containing;
Kcnh, potassium voltage-gated channel, subfamily H; Slc, solute carrier; Socs, suppressor of cytokine signaling.
2.3. Regulation of Swiprosin-1 Expression in Pig Hearts
The aforementioned experiments have shown that swiprosin-1 is up-regulated during cardiac
repair processes in small rodents. To investigate the relevance for other species as well, the investigation
was extended by analysis of swiprosin-1 expression in pig hearts. This analysis was performed on pig
heart samples previously analyzed in more detail [18,19]. Tissue samples were taken 3 h and 3 days after
reperfusion from the border zone, infarct zone, and unaffected control zone. Again, swiprosin-1 mRNA
expression was induced at the late time-point (day 3) in the infarct zone (Figure 5A). In comparison,
expression of proinflammatory markers such as MCP-1 was induced already after 3 h (Figure 5B).
Finally, in the reperfused heart, ssc-miR-34c was again increased by ischemia/reperfusion, and this was
again abrogated by IPC and IPoC.
Figure 5. Cont.
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Figure 5. Expression of swiprosin-1, MCP-1, and ssc-miR-34c in the border zone (BZ) or infarct zone
(IZ) three hours or 3 days after reperfusion. The quantification for ssc-miR-34c was performed in
the infarct zone 3 h after reperfusion.
3. Discussion
Swiprosin-1 is expressed in various tissues, but although its expression and function in adult rat
ventricular cardiomyocytes have been reported before, a proof of concept is still lacking that will show
that swiprosin-1 is expressed in cardiac tissue and furthermore differentially regulated during active
repair processes. Postinfarct remodeling requires extensive cardiac reconstruction and is therefore
suitable to address this question. Using different conditioning protocols (IPC and IPoC), infarct sizes
and thereby the amount of repair process can be modified. In line with these assumptions, the main
findings of the current study are that swiprosin-1 expression is induced during cardiac repair processes
in mice, rats, and pigs. Moreover, the expression of swiprosin-1 is strongest in those areas of the heart
where cardiac remodeling occurs, that is, in the border zone of MI mice hearts and in the infarct
zone of reperfused rat and pig hearts. Finally, histology identified cardiomyocytes as the main side
of expression.
Our study is based on the assumption that swiprosin expression in cardiomyocytes is
transcriptionally regulated. This argument comes from our previous study showing that targeting
swiprosin mRNA by siRNA reduces swiprosin protein expression as well. In our current study,
we show swiprosin protein expression in mice and confirmed its expression on mRNA in rat and pig.
This expression is associated with miR expression, indicating a complex regulatory network in
cardiomycytes. Nevertheless, on the basis of the material used in this study we could not directly
confirm a strict coregulation of swiprosin mRNA and swiprosin protein for the three species, and this
is of course a limitation of the study.
In the process of cardiac remodeling, a coordinative regulation of genes that encode for proteins
required for cardiac contractility and excitation is required. As a potential mechanism to coordinate
such expression, miRs are interesting molecules as the predicted consensus sequence of these molecules
potentially targets multiple mRNAs. It was already known that in cardiomyocytes swiprosin-1
is coregulated with the mRNA expression of proteins linked to β-adrenoceptor desensitization.
A desensitization of β-adrenoceptors can occur under conditions of cardiac cell cultivation and in
the postischemic heart [16]. Nevertheless, coregulation of cardiac expression of swiprosin-1
and arrestin-2 in vivo has not been demonstrated before. Screening potential miRs that may trigger
this coregulation, two miRs were identified. Both showed a similar type of regulation of expression
to swiprosin-1, namely, rno-miR-32-3p and rno-miR-34c-3p. The amount of expression of both miRs
correlates with swiprosin-1 and arrestin-2.
Rno-miR-32-3p was also associated with other genes that are well known to affect cardiac
remodeling. The level of miR expression correlated with genes involved in fibrosis (biglycan, collagen-1,
collagen-3, and fibronectin), inflammation (iNOS, arginase-2), and receptor activity (RAMP-3). Biglycan
and fibronectin can act as a modulator of TGF-β1 activity, and in line with this function the expression
of collagen increased [20,21]. RAMPs, but not RAMP-3, are differentially expressed in cardiomyocytes
under hypertensive conditions [22]. On the other hand, increased expression of rno-miR-32-3p was
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inversely correlated with the expression of sarcomeric proteins (MHC-α, troponin T), transporters of
sodium (NCX, Scl5a3), and that of fatty acid metabolism (HADHA, UCP-2). While HADHA is required
for fatty acid metabolism, down-regulation of UCP-2 will favor glucose utilization [23]. Therefore,
the down-regulation of HADHA and UCP-2 both initiate a metabolic switch into the direction of
glucose metabolism. In general, the common regulation of swiprosin-1 with other proteins known
to be differentially regulated during cardiac remodeling suggests that swiprosin-1 is part of this
program. However, as most of the adaptations (fibrosis, metabolic switch, and sarcomere remodeling)
are associated with maladaptive function, the overall function of swiprosin-1 may be maladaptive
as well. As swiprosin-1 participates in cardiomyocyte dedifferentiation, a mechanism that leads to
impaired cardiac function when occurring in a chronic rather than acute way, this may indeed be
the case. In this way, the lower expression of swiprosin-1 after IPC and IPoC will be the consequence
of smaller infarct sizes.
In contrast, rno-miR-34c-3p was not associated with maladaptive gene reprogramming such as
rno-miR-32p. This miR, in addition to swiprosin-1, was associated with down-regulation of four
different ion transporters. Of note, I/R-dependent regulation of miR-34c was found in rat and pig
tissues. Finally, both miRs identified in this study have not yet been associated with myocardial
remodeling and represent another new finding of this study.
The design of the current study does not allow identifying potential mechanisms by which
swiprosin-1 may affect the remodeling process. However, it has been shown before that dedifferentiation
processes are needed for regeneration of cardiomyocytes. Such processes depend on oncostatin M
as well as of swiprosin-1 [24]. In this context, it was also shown that swiprosin-1 and oncostatin M
are coexpressed and coregulated in cardiomyocytes in vitro [12]. Oncostatin M may link the initial
inflammatory process during cardiac repair to cardiac remodeling, and this process may require
swiprosin-1 to arrange sarcomeric structures.
In the current study, swiprosin expression was found in the same region of mouse tissue
and at the same time-point as oncostatin M (this study and ref. 24). Oncostatin M is released by
immune cells like macrophages and triggers the release of Reg3β from cardiomyocytes. Reg3β directs
more oncostatin M, releasing immune cells to this area. At the same time, oncostatin M triggers
the dedifferentiation of cardiomyocytes. This process requires swiprosin [9]. Therefore, oncostatin
M-producing immune cells like macrophages may potentiate the induction of swiprosin expression
at the site of cardiac differentiation.
In conclusion, this study highlights the tissue-specific expression of swiprosin-1 in postinfarct
hearts, and the way of regulation suggests an important role in cardiac repair.
4. Materials and Methods
4.1. Animal Experiments
All types of analysis in this study were performed on tissue samples from previous experiments.
Therefore, no new animal experiments were performed for this study. The samples for analysis of
mice tissue were generated in a mouse MI model as described before [24]. Briefly, the model used
a permanent ligature of the LAD in mice with a subsequent 4 and 7 days follow-up before the mice
were sacrificed. All relevant functional data were published before [24]. The samples for analysis of
rat tissue were generated in a rat model of ischemia/reperfusion as described [16]. This model uses
a 30 min LAD occlusion with subsequent reperfusion for 7 days. All relevant functional data were
published before [16,17]. Infarct sizes were quantified by increased plasma troponin I levels 60 min
after reperfusion as described before [16]. The samples for analysis of pig tissue were generated in
a pig model of I/R as described [18,19]. This model is based on a 90 min percutaneous balloon occlusion
of the left anterior descending coronary artery, followed by balloon deflation in anaesthetized pigs
and subsequent reperfusion for 3 h or 3 d.
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4.2. Western Blot and Histology on Mouse Samples
Infarcted hearts of adult mice were harvested and dissected in an infarction zone and remote
myocardium (basal part of the interventricular septum) for Western Blot analysis. Fractionated samples
were sonicated in lysis buffer (0.1 M Tris-HCl pH 8.8, 0.01 M EDTA, 0.04 M DTT, 10 % SDS, and pH
8.0) supplemented with protease inhibitors. Twenty micrograms of each protein sample were loaded
on Gradient NuPAGE 4-12% Bis-Tris gels (Invitrogen) to perform SDS-PAGE. After transferring onto
nitrocellulose membranes (Invitrogen), immunoreactive proteins were visualized on the ChemiDocXRS+
System (BioRad) and analyzed by using the Image Lab software (BioRad). The following antibodies
for Western Blot analysis were used: goat anti-Swiprosin-1 antibody (Sigma-Aldrich, catalogue
no. SAB2501007) and rabbit anti-Pan-actin antibody (Cell Signaling Technology, catalogue no. 4968).
Secondary antibodies conjugated with horseradish peroxidase were purchased from R&D Systems.
The method for immunohistochemical analysis of murine infarcted hearts has been
previously described (24). The following antibodies for immunofluorescence staining were used:
goat anti-Swiprosin-1 antibody (Sigma-Aldrich, catalogue no. SAB2501007) and rabbit anti-α
-sarcomeric-actinin monoclonal antibody (Clone: EA-52, Sigma-Aldrich, catalogue no. A7732).
For nuclear counterstain, 4′,6-diamidino-2-phenylindole (DAPI) was used (Sigma Aldrich, catalogue
no. D9542). Lectin from Ulex europaeus (L4895; catalogue no. L4895; Sigma Aldrich) was used to detect
intact cells.
4.3. RT-PCR on Rat and Pig Tissue
The method on RNA isolation and real-time reverse-transcriptase polymerase chain reaction
(RT-PCR) used to quantify the mRNA expression has been described before in detail [16]. A list of all
rat primers used in the study has also published before [17] Table 3.
Table 3. List of porcine primers used in this study.
Beta-2-Mircoglobulin forward: CGT GGC CTT GGT CCT GCT CG reverse: TCC GTT TTC CGC TGG TGT GC
EFhD2 forward: TCC GGG AGT TCC TCC TGA TT reverse: AAG CTC TTC GCT CCC TTG AC
MCP-1 forward: CAG CCA CCT TVT GCA CCC AGG Reverse: CAC AGA TCT CCT TGCCCG CGA
4.4. Statistics
Group comparison was performed by One-Way-ANOVA and Student–Newman–Keuls post hoc
analysis. If the probability to belong to equal groups is below p≤0.05, this is indicated by different
letters in the figures. Correlation analysis was performed by Pearson correlation. Exact p values for
correlation analysis are given in the figures to the legend.
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